Leman Biotech and the team led by Professor Huang He from the First Affiliated Hospital of Zhejiang University School of Medicine have entered into a clinical trial collaboration agreement on the safety and efficacy of the metabolism-enhanced CD19 CAR-T cell injection (Meta10-19 CAR-T) in treating relapsed or refractory diffuse large B-cell lymphoma.

From June to July 2022, Professor Li Tang, co-founder of Leman Biotech, and his team were invited to attend two Gordon Research Conferences (GRCs) held in Rhode Island and Ventura, USA. These conferences were among the top events in the field. 

Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), a new biotech company specializing in cancer immunotherapy drug R&D, has completed a successful angel round of financing, raising $11 million. The round was led by Tiantu Capital, with support from 5Y Capital and XtalPi.